# Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.

Study · id `cardio:ct-nct04507061` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04507061](<https://clinicaltrials.gov/study/NCT04507061>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04507061

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.

## Technical summary

Registry record NCT04507061. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-01 (actual); primary completion 2022-03-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 243 participants (enrolled count; ClinicalTrials.gov record NCT04507061, source copy `cardio:ctgov-nct04507061-2023-04-04`, retrieved 2026-10-26)
- Started: 2020-09-01 (actual) (ClinicalTrials.gov record NCT04507061, source copy `cardio:ctgov-nct04507061-2023-04-04`, retrieved 2026-10-26)
- Primary completion: 2022-03-08 (actual) (ClinicalTrials.gov record NCT04507061, source copy `cardio:ctgov-nct04507061-2023-04-04`, retrieved 2026-10-26)
- Completion: 2022-04-05 (actual) (ClinicalTrials.gov record NCT04507061, source copy `cardio:ctgov-nct04507061-2023-04-04`, retrieved 2026-10-26)
- Countries: Austria; Belgium; Bulgaria; Denmark; Finland; Germany; Israel; Italy; Poland; Slovakia; Spain; Sweden; Ukraine (ClinicalTrials.gov record NCT04507061, source copy `cardio:ctgov-nct04507061-2023-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04507061-2023-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
- Acronym: CONCORD
- Condition: Chronic Kidney Disease
- Intervention (Drug): runcaciguat
- Intervention (Other): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial (`cardio:pubmed-39656628`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: be272ecd8e8d41b54cb0412955bd24672118a109423e8710e8c184e471cb757a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
